Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149377 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4HPGDLMNAMAPT | |
| SCHEMBL8901225 | 0.94 | CHRNB2 (0.64) | CHRNB2CHRNA4HPGDLMNAMAPT | |
| Hydrochloric Acid SCHEMBL3037290 | 0.92 | CHRNB2 (0.62) | CHRNB2CHRNA4HPGDLMNAMAPT | |
| SCHEMBL14028449 | 0.92 | CHRNB2 (0.69) | CHRNB2CHRNA4HPGDLMNAMAPT | |
| SCHEMBL7873589 | 0.89 | CHRNB2 (0.66) | CHRNB2CHRNA4HPGDLMNALTA4H | |
| SCHEMBL3977089 | 0.88 | CHRNB2 (0.64) | CHRNB2CHRNA4HPGDLMNAMAPT | |
| Hydrochloric Acid SCHEMBL5405414 | 0.88 | CHRNB2 (0.64) | CHRNB2CHRNA4HPGDLMNALTA4H | |
| SCHEMBL15498199 | 0.85 | CHRNB2 (0.73) | CHRNB2CHRNA4HPGDLMNAMAPT | |
| SCHEMBL8955653 | 0.85 | CHRNB2 (0.61) | CHRNB2CHRNA4HPGDLMNAMAPT | |
| SCHEMBL5973196 | 0.85 | CHRNB2 (0.65) | CHRNB2CHRNA4HPGDLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198284-B2 | Treatment of neurodegenerative disorders with thiourea compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-06-12 | — | — | US | disclosed |
| US-7897764-B2 | Thiourea derivatives | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-03-01 | — | — | US | disclosed |
| US-20090275596-A1 | Treatment of Neurodegenerative Disorders with Thiourea Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| WO-2008154091-A1 | THIOUREA DERIVATIVES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306090-A1 | THIOUREA DERIVATIVES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275596-A1 | Treatment of Neurodegenerative Disorders with Thiourea Compounds | CLN6, MSR1, TPMT | CHRNB2 114/4885CHRNA4 270/4885HPGD 3406/4885 |
| US-20080306090-A1 | THIOUREA DERIVATIVES | EIF2AK2, IFNAR1, TPMT | CHRNB2 4538/4885CHRNA4 4301/4885HPGD 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.